
Sign up to save your podcasts
Or


Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content:
By JAMA Network4.4
472472 ratings
Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content:

319 Listeners

542 Listeners

706 Listeners

165 Listeners

258 Listeners

895 Listeners

3,366 Listeners

38 Listeners

22 Listeners

13 Listeners

12 Listeners

7 Listeners

17 Listeners

19 Listeners

5 Listeners

7 Listeners

1,150 Listeners

30 Listeners

9 Listeners

92 Listeners

145 Listeners

14 Listeners

5 Listeners

516 Listeners

5 Listeners

375 Listeners

257 Listeners

442 Listeners

106 Listeners

17 Listeners

312 Listeners

2 Listeners

327 Listeners

270 Listeners